CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It contains four strategic amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that enhance enzymatic stability over native GHRH (1-29) / Sermorelin while retaining a short half-life of approximately 30 minutes. This pulsatile profile distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which has an extended ~6-8 day half-life via albumin binding. The "No DAC" variant is widely used in research models examining short-acting GHRH analog activity, frequently paired with Ipamorelin for combined GHRH/GHS pathway research.
BENEFITS
GHRH receptor binding — studied as a stabilized GHRH analog with enhanced enzymatic resistance
Pulsatile profile — short half-life (~30 min) preserves natural GH release patterns
Stack compatibility — commonly paired with Ipamorelin in dual-pathway GH research
Modified GRF identity — well-documented in published GHRH literature
Research convenience — single 10mg vial for extended research protocols
WHAT RESEARCHERS LOOK AT
Pulsatile growth hormone release in pituitary cell models
IGF-1 secretion patterns following GHRH analog administration
Comparative half-life studies vs. native GHRH (1-29) and CJC-1295 (DAC)
Synergy with ghrelin receptor agonists like Ipamorelin
Bone density and longitudinal growth research models
